Advances on the relationship between thrombin-activatable fibrinolysis inhibitor (TAFI) and recurrent pregnancy loss
10.3969/j.issn.0253-9896.2015.03.028
- VernacularTitle:凝血酶激活的纤溶抑制物与反复妊娠丢失关系的研究进展
- Author:
Xiaofang YI
;
Chao TAN
- Publication Type:Journal Article
- Keywords:
thrombin;
plasminogen inactivators;
abortion,habitual;
review;
thrombin-activatable fibrinolysis inhibitor
- From:
Tianjin Medical Journal
2015;(3):327-329
- CountryChina
- Language:Chinese
-
Abstract:
Recurrent pregnancy loss (RPL) is a common complication of pregnancy, which affects 2%fertile women. A recent research has found that high level of thrombin-activatable fibrinolysis inhibitor (TAFI) can reduce the occurrence risk of early RPL. TAFI is one kind of carboxypeptidase, which can be activated as TAFIa. TAFIa can make the fibrinolysin lose its working site, which can interact with the fibrin to play a role in the regulation of fibrinolysis and the inhibition of throm?bus formation. The damage of fibrinolytic system is one of the risk factors for the occurrence of RPL in pregnant women, which has become one of the hotspots in the medical profession. In this paper, recent literature on TAFI and its relationship with recurrent pregnancy loss has been reviewed, hoping for new ways and clues in clinical treatment and prevention of RPL.
